In just the past five years, significant changes have occurred in how new drugs come to market. Demands for real world evidence and patient-reported outcomes are changing how and when new drugs file for approval. Accountable care organizations (ACOs), integrated delivery networks (IDNs), advocacy groups and payers are increasingly flexing their muscles. Tried-and-true paths to commercialization have developed new twists and turns, and the ecosystem has become more complicated. Dominic Marasco, RPh, Executive Vice President for Global Business Development and Commercial Solutions at Syneos Health, shares five of the most important changes re-shaping drug commercialization with BioPharma Dive.
Read the full article here.